Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.

BACKGROUND AND PURPOSE The aims of this study were to develop a clinical assessment scale to measure functional ability in ambulant boys with Duchenne muscular dystrophy and to determine the reliability of the scale in multiple centres in the UK. METHODS Focus groups and workshops were held with experienced paediatric neuromuscular physiotherapists to determine scale content. A manual was prepared with accompanying videos, and training sessions were conducted. A total of 17 physiotherapists from participating centres used the videos to determine inter-rater reliability. Five determined the intra-rater reliability. RESULTS Strength of agreement for these groups based on total subject scores was very good (0.95 and ≥ 0.93 for consistency and absolute agreement, respectively). Test-retest ability was high, with perfect agreement between occasions for all but two items of the scale. CONCLUSIONS Our study indicates that the North Star Ambulatory Assessment is practical and reliable. It takes only 10 minutes to perform and incorporates both universally used timed tests as well as levels of activities, which allow assessment of high-functioning boys with Duchenne muscular dystrophy.

[1]  Jay J. Han,et al.  The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.

[2]  F. Muntoni,et al.  P01 Current progress with the systemic administration trial of AVI-4658, a novel Phosphorodiamidate Morpholino Oligomer (PMO) skipping dystrophin exon 51 in Duchenne muscular dystrophy (DMD) , 2010, Neuromuscular Disorders.

[3]  J. Varni,et al.  The PedsQL™ in Pediatric Patients with Duchenne Muscular Dystrophy: Feasibility, Reliability, and Validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales , 2010, Journal of clinical neuromuscular disease.

[4]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.

[5]  M. Main,et al.  Reliability of the North Star Ambulatory Assessment in a multicentric setting , 2009, Neuromuscular Disorders.

[6]  F. Muntoni,et al.  Update on the management of Duchenne muscular dystrophy , 2008, Archives of Disease in Childhood.

[7]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2008, The Cochrane database of systematic reviews.

[8]  T. O'Shea.  Definition and classification of cerebral palsy — an epidemiologist perspective , 2007 .

[9]  R. McCarter,et al.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy , 2007, Muscle & nerve.

[10]  Elaine Scott MPhil Mcsp,et al.  Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool , 2006 .

[11]  Carole Bérard,et al.  La mesure de fonction motrice, outil d’évaluation clinique des maladies neuromusculaires. Étude de validation , 2006 .

[12]  J. Fermanian,et al.  [A motor function measurement scale for neuromuscular diseases - description and validation study]. , 2006, Revue neurologique.

[13]  Malcolm Kohler,et al.  Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy. , 2005, American journal of respiratory and critical care medicine.

[14]  Jacques Fermanian,et al.  A motor function measure scale for neuromuscular diseases. Construction and validation study , 2005, Neuromuscular Disorders.

[15]  L. Rajmil.  Health measurement scales. A practical guide to their development and use, 3rd ed , 2005 .

[16]  David M. Wilson,et al.  Validity of measurements of calcium absorption , 1995, Pediatric Nephrology.

[17]  Jacques Fermanian,et al.  A motor function measure for neuromuscular diseases. Construction and validation study. , 2005, Neuromuscular disorders : NMD.

[18]  A. Manzur,et al.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy. , 2004, The Cochrane database of systematic reviews.

[19]  C. McDonald.  Physical activity, health impairments, and disability in neuromuscular disease. , 2002, American journal of physical medicine & rehabilitation.

[20]  E. Mattsson,et al.  Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. , 2002, Developmental medicine and child neurology.

[21]  E. Mattsson,et al.  Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. , 2001, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[22]  C. Dollaghan,et al.  The Notion of Clinically Significant Change , 1991 .

[23]  D. Streiner,et al.  Health Measurement Scales: A practical guide to thier development and use , 1989 .

[24]  V. Dubowitz,et al.  Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy , 1982, Muscle & nerve.

[25]  M. Brooke,et al.  Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.

[26]  Jacob Cohen,et al.  The Equivalence of Weighted Kappa and the Intraclass Correlation Coefficient as Measures of Reliability , 1973 .

[27]  P. Vignos,et al.  Management of progressive muscular dystrophy in childhood. , 1963, JAMA.